Biogen Inc. (BIIB) was upgraded to a "buy" by TheStreet's Quant Ratings service on Wednesday. This biotech name has made a chart that could be challenging to many traders and investors. Let's drill down and see if an easier approach to the long side can be found.
More from Stocks
We're seeing a good variety of action, and stocks with superior fundamentals and charts are doing well.
We'll witness some action in Suro Capital, which has an ownership stake dating back to when Palantir was private.
I wouldn't recommend shorting the stock ahead of earnings on Thursday.
NIO is trading just below 'new closing high' levels. A similar level was the catalyst for a breakout move in late August.